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Abstract Five-year survival for patients with oral cancer has
been disappointingly stable during the last decades, creating a
demand for new biomarkers and treatment targets. Lately,
much focus has been set on immunomodulation as a possible
treatment or an adjuvant increasing sensitivity to conventional
treatments. The objective of this study was to evaluate the
prognostic importance of response to radiotherapy in tongue
carcinoma patients as well as the expression of the CXC-
chemokines in correlation to radiation response in the same
group of tumours. Thirty-eight patients with tongue carcino-
ma that had received radiotherapy followed by surgery were
included. The prognostic impact of pathological response to
radiotherapy, N-status, T-stage, age and gender was evaluated
using Cox’s regression models, Kaplan-Meier survival curves
and chi-square test. The expression of 23 CXC-chemokine
ligands and their receptors were evaluated in all patients using
microarray and qPCR and correlated with response to treat-
ment using logistic regression. Pathological response to radio-
therapy was independently associated to overall survival with
a 2-year survival probability of 81 % for patients showing a
complete pathological response, while patients with a non-
complete response only had a probability of 42 % to survive
for 2 years (p=0.016). The expression of one CXC-
chemokine, CXCL10, was significantly associated with re-
sponse to radiotherapy and the group of patients with the
highest CXCL10 expression responded, especially poorly (p
=0.01). CXCL10 is a potential marker for response to radio-
therapy and overall survival in patients with squamous cell
carcinoma of the tongue.
Keywords Oral cancer . Tongue . Chemokines . CXCL10 .
Radiotherapy . Prognosis
Introduction
Squamous cell carcinoma (SCC) in the oral cavity is one of the
ten most common malignancies worldwide, with the tongue
being the most tumour prone sub-site. The relatively low 5-
year survival, of around 50 %, has remained disappointingly
stable over the last few decades in spite of improvements in
the main treatments of surgery and radiotherapy [1–3]. This
has evoked a rising interest in identifying biomarkers that are
able to predict prognosis and response to treatment [2]. Today
the most informative marker is node status, N-status, where
cervical lymph node involvement drastically worsens the
prognosis [4, 5]. A complicating factor is the fairly high rate
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of occult cervical nodal metastasis, which is especially fre-
quent in tumours of the tongue (∼30 %) [3].
Several factors are known to influence response to radio-
therapy in head and neck cancer patients, including tumour
characteristics (e.g. location, volume and tumour stage), pa-
tient characteristics (e.g. smoking status) and biological fac-
tors (e.g. hypoxia and expression of DNA repair genes) [6–9].
The potential of the natural immune response for improving
response to conventional treatments has recently been in focus
[10–12]. The goal is to enhance the anti-tumoural specific
response, which can be achieved either by nonspecific or
specific stimulation of the immune system. The immune re-
sponse towards tumours is, however, a complex process,
involving both pro- and anti-tumour components and research
on the interaction between tumours and the microenvironment
is still fairly young.
Chemokines are small secreted immune modulators
representing a large family of proteins that were initially
characterized as attractants of leucocytes. They signal through
G-protein-coupled (chemokine) receptors and are divided into
four subgroups (CC, CXC, CX3C and C), depending on
structure, with CC and CXC representing the major classes.
CXC-chemokines were initially closely related to angiogene-
sis and are further divided into angiogenic and angiostatic but
are also reported to be important for cell survival and metas-
tasis [12]. Several CXC-chemokine ligands activate more than
one receptor, and the majority of the receptors bind several
CXC-ligands. They are induced by inflammatory cytokines,
growth factors and pathogenic stimuli and are produced and
secreted by many different cell types including tumour cells
and tumour-infiltrating immune cells.
In addition to their importance for tumour survival, metas-
tasis and angiogenesis, chemokines have recently been impli-
cated in treatment response [12]. A number of studies have
shown a considerable effect of radiation on chemokine ex-
pression, and there are indications for a role for chemokines in
resistance to chemo- and radiotherapy [13–16]. Chemokines
are interesting molecular targets due to their properties as
natural immune modulators, and monoclonal antibodies
against chemokine receptors have been used in experimental
settings to inhibit growth and spread of malignant tumours
[17, 18]. The role and expression of many chemokines are not
yet well established in oral cancer, but a study mapping the
expression of 24 chemokine ligands and receptors in a number
of SCC head and neck cell lines before and after radiation was
recently published. This study showed large variation in che-
mokine receptor and ligand expression, and further evaluation
of chemokines as biomarkers for radiation response was sug-
gested to be of value [19].
The aim of this study was to summarize the expression of
CXC-chemokines in tongue tumours and investigate the rela-
tionship to radiation response. Additionally, the association
between radiation response and 5 year survival in tongue
tumour patients was assessed, as response to preoperative
treatment has prognostic value in some other solid tumours,
including tonsillar carcinoma [20–22]. Results showed a
strong association between radiation response and overall
survival for tongue tumour patients and identified CXCL10
as a candidate chemokine for predicting radiation response.
Patients and methods
Patients
Thirty-eight patients for which response to radiotherapy could be
evaluated were identified from a previous study on stromal
inflammation and tongue cancer [23]. These patients had re-
ceived and completed preoperative radiotherapy, and surgery
and pathological evaluation of the response to radiotherapy were
performed on surgical specimens at the ENT Clinic, Norrlands
University Hospital. The pathological response was judged as
complete (cPR) if no viable cancer cells could be detected and as
incomplete (non-cPR) if viable cancer cells were detected. Pa-
tients were classified as young if diagnosed before 40 years of
age and classified as old if over 40 years at diagnosis, in accor-
dance with the literature [24–29]. The studywas approved by the
local ethics committee (dnr 01-210; dnr 08-003M)
Array data
Microarray data from samples taken at diagnosis for all 38
patients had previously beenmade publically available at gene
expression omnibus (GEO) (accession number GSE34115),
and data for 16 of the 17 CXC-chemokine ligands and all 7
chemokine receptors were extracted [30]. Even though data
for 24 more tongue tumours were available, we focused on the
38 patients for which pathological response to radiotherapy
could be evaluated. The chemokine ligand CXCL15 was not
available on the microarray chip and therefore not included in
the study. Array data for normal tongue tissue from 16 con-
trols also included in the above study was used for
comparison.
qPCR data
Expression of the chemokine ligand CXCL10 was evaluated
using qPCR in all samples. Relative quantities were calculated
using the ΔCT method. The gene TUBA6, previously demon-
strated to be stably expressed in oral FFPE tissue, was used as
reference gene [31, 32]. cDNA reactions were performed using
RevertAid H minus first strand cDNA kit (Fermentas Gmbh,
Leon-Rot, Germany) with 200 ng of RNA. For the PCR reac-
tions, the quanti tect primer assay was used for CXCL10 and in-
house designed primers for TUBA6 together with the quanti tect
SYBR green assay (Qiagen Gmbh, Hamburg, Germany) [32].
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Statistical analysis
Correlations between the 2-year survival and age, gender, T-
stage, N-status and pathological response to radiotherapywere
investigated by chi-square tests, and Cox’s regression models
were used to assess their prognostic value. Survival curves
were drawn using the Kaplan-Meier method, and the log rank
test was used to assess the survival difference between groups.
Fold changes and significances (tumour vs control) for the
CXC-chemokines were calculated using array data. A value
above or below the mean expression of controls plus/minus
two standard deviations (mean control ±2*SD) was used as a
cut-off to decide how many tumours had increased/decreased
expression of the separate CXC-chemokines. Array data for
all CXC-chemokines and qPCR data for CXCL10 were used
to correlate expression levels to pathological response to
radiotherapy using logistic regression, both in a univariate
analysis and a multivariate model correcting for gender, age,
size of tumour and nodal status. Expression of CXCL10 was
additionally categorized into three similar sized groups, low (n
=13), medium (n=12) and high expression (n=13), to further
evaluate its relationship to pathological response to radiother-
apy. The significance level was set to p<0.05, and all analysis
were performed using SPSS software version 19.0 (SPSS Inc.,
Chicago, IL, USA)
Results
Clinical data
Clinical data is summarized in Table 1. The male to female
ratio was 1.2:1, and most patients presented with a T1 or T2
tumour (76 %). The age span was 19–81 years, with a mean
age of 50 years, which is slightly lower than the typical patient
group. This could partially be caused by a larger proportion of
the older patients being judged as unfit for surgery in contrast
to more of the younger patients completing both radiotherapy
and surgery. Pathological response to radiotherapy was eval-
uated in surgical samples from all 38 patients; 26 patients
showed complete response (cPR) and 12 did not (non-cPR).
For three patients with non-cPR, the tumour was not radically
removed at surgery. One of these patients went through ex-
tended surgery, showing tumour-free resection margins, and
two were treated with cytostatics. All patients had been
followed for at least 2 years or until death.
Importance of complete response to preoperative radiotherapy
for overall survival
Univariate survival analysis by Cox’s regression of the vari-
ables pathological response to radiotherapy, gender, age, T-
stage or N-status identified pathological response to treatment
as the only variable significantly correlating to overall survival
(hazard ratio (HR) 95 % confidence interval (CI), 6.0 (2.1–
16.9), p=0.001). Multivariate analysis further demonstrate
that pathological response to radiotherapy was an indepen-
dently unfavourable prognostic factor (HR 95 % CI, 5.3 (1.7–
16.9), p=0.005). Chi-square test showed that a cPR was
already important for the 2-year survival (p=0.016), with
81% probability of surviving 2 years when having a complete
response to radiotherapy as compared to 42 % for patients
with non-cPR. Survival curves for patients with a non-cPR as
compared to patients with cPR can be found in Fig. 1a and it
illustrates a significantly poorer overall survival for patients
with a non-cPR (p<0.001, log rank test). After removing the
three patients for whom initial surgery did not radically re-
move the tumour from the analysis, results remain significant
(p=0.002, log rank test).
Expression of the CXC family of chemokines
and their receptors in tongue tumours
RNA from all 38 patients and probes for detection of all but
one of the 24 CXC-chemokine ligands and receptors were
Table 1 Summary of
patients data
a One patient had un-
known N-status
b Five year follow-up not
yet passed
Number (%)
Age at diagnosis
Mean 50
Range 19–81
Gender
Male 21 (55)
Female 17 (45)
Tumour size
T1 10 (26 )
T2 19 (50 )
T3 7 (19)
T4 2 (5)
Nodal statusa
N− 29 (78 )
N+ 8 (22 )
Pathological response to radiotherapy
cPR 26 (68 )
Non-cPR 12 (32 )
2-year survival
Yes 26 (68)
No 12 (32 )
5-year survival
Yes 18 (47)
No 15 (40 )
NAb 5 (13 )
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included in a previously published microarray study made
public on GEO [30], and their expression in tongue tumours
as compared to controls is summarized in Fig. 2. Five of the
CXC-chemokines (CXCL3, 4, 9 and 16 and CXCR4) had a
detection p value above 0.05 (caused by low signal or low
stringency), and data for these should thus be interpreted with
care. Eight CXC-chemokine ligands were significantly up-
regulated (CXCL1, 2, 5, 6, 8, 10, 11, 13), and none were
significantly down-regulated. Of the receptors, three were
significantly up-regulated (CXCR3, 5, 6) and one (CXCR1)
significantly down-regulated. CXCL10 had the highest fold
change with an average increase of 16-fold. For some
chemokines, a changed expression (>mean control ±2*SD)
could be seen in almost all patients, while other chemokines
were only increased or decreased in a subgroup of patients
summarized in Table 2.
Association between the expression of CXCL10 and response
to radiotherapy
Using continuous array data and logistic regression to inves-
tigate the association between CXC-chemokine ligand and
receptor expression in response to radiotherapy, one chemo-
kine, CXCL10, was found to be significant (p=0.03), with
higher levels resulting in a poorer response to radiotherapy.
Because of the somewhat noisy nature of microarray data,
CXCL10 levels were analysed using qPCR to obtain more
accurate expression values before further evaluating the rela-
tionship with radiotherapy response. The correlation between
the two methods (qPCR and microarray) was good (R=0.76).
In a multivariate logistic regression model, correcting for
gender, age, size of tumour and nodal-status, CXCL10 ex-
pression was again significantly associated with response to
radiation therapy (p=0.05). Categorising samples into three
equal groups according to CXCL10 expression (low, medium,
high) showed that patients with the highest expression of
CXCL10 had significantly poorer pathological response to
radiotherapy compared to patients expressing the lowest
levels (p=0.01) (Table 3). Survival analysis of patients ac-
cording to the categorised CXCL10 expressions showed sig-
nificantly better survival in the group with the lowest expres-
sion of CXCL10 (p=0.017, log rank test) (Fig. 1b).
Discussion
In spite of the easily accessible location of tumours in the oral
cavity, both from a diagnostic and a therapeutic point of view,
survival is fairly low and patients die from metastatic disease,
loco-regional recurrence and second primary tumours. In this
study, we found that complete response to preoperative radi-
ation is important for survival in tongue cancer patients and
that CXCL10 expression could indicate resistance to
radiotherapy.
Response to preoperative treatment has previously been
shown to be a strong prognostic marker for a number of
cancers. In a large study on 167 tonsillar carcinomas, Fries-
land and co-workers found that the probability of surviving
5 years when displaying complete response to radiotherapy
was 79 %, while it was only 9 % for patients showing
incomplete response (p=<0.0001) [21]. Similar results were
achieved when looking at cervical cancer stage Ib and IIa and
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Fig. 1 Kaplan-Meier survival curve showing a the relationship between
pathological response to radiotherapy (cPR vs non-cPR) and overall
survival. b The relationship between grouped CXCL10 expression (low,
medium, high) and overall survival censoring of patients is shown as
vertical lines
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preoperative radiotherapy (5-year survival cPR=95 % and
non-cPR=46 %, p<0.0001) as well as breast cancer and
preoperative chemotherapy (5-year survival cPR=88 % and
non-cPR=77 %, p<0.033) [20, 22]. In our cohort of tongue
tumour patients, a cPR after preoperative radiotherapy result-
ed in a 2-year survival of 81 %, while patients with a non-cPR
only had 42 % probability of surviving 2 years (p=0.016),
confirming the importance of radiotherapy response also in
these patients.
N-status is a well-known predictor of prognosis, and the
fact that no significance was obtained in this study is probably
partially due to the small number of N+ patients (n=8). The
high number of expected occult metastasis in tongue tumours
(∼30 %) also decreases the sensitivity of the analysis [3]. The
survival of young tongue cancer patients is a much debated
subject, and there are as many studies showing no difference
or an even better prognosis in young patients as there are
studies showing a poor prognosis [24–29, 33]. In this small
cohort of 38 patients, we did not see any significant difference
in overall survival between young and old patients.
CXC-chemokines has previously been connected to re-
sponse to treatment, but their roles in cancerogenesis differ
between tumour types. We therefore wanted to clarify which
CXC-chemokines have a changed expression in tongue tu-
mours and their relation to radiation resistance. The tongue
additionally differs morphologically from other tissues in the
oral cavity, and it has recently been shown that both normal
and malignant tongue tissue are molecularly distinct from
other tissues within the region, indicating that collectively
analysing all tissues in the oral cavity as done historically
could be misleading [34, 35]. In our study, eight CXC-
chemokine ligands and three receptors were significantly up-
regulated and one receptor was significantly down-regulated
in tongue tumours. Expression of one of the CXC-ligands,
CXCL10, was strongly associated to radiation response.
Categorising CXCL10 expression into three groups showed
that it was especially patients with the highest expression of
CXCL10 that respond poorly to radiotherapy.
Fig 2 Summary of microarray expression data for all CXC-chemokine
ligands (oval) and receptors (squares), except CXCL15, in tongue tu-
mours compared to normal controls. Colour indicates significance as
defined in the figure. P<2.4E-6 is the Bonferroni corrected significance
level recommended when all genes in a 20 818 gene array is tested. Only
two genes fall below this level. Fold changes can be found in each shape
Table 2 Percentage of
samples with increased/
decreased expression of
the significant CXC-li-
gands and receptors
a The only gene showing
decreased expression in
tumours
Gene %
CXCR6 43
CXCR1a 50
CXCL5 57
CXCL2 61
CXCL8 68
CXCR5 68
CXCR3 71
CXCL11 71
CXCL1 82
CXCL10 89
CXCL13 89
CXCL6 93
Table 3 Logistic regression after categorising CXCL10 expression into
low, medium and high
pvalue OR and 95 % CI
CXCL10 expression (high vs low) 0.01 19.2 (1.88–196.53)
CXCL10 expression (high vs medium) 0.07 4.8 (0.86–26.79)
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CXCL10 has an unclear role in cancer. It is angiostatic and
as expected has anti-tumour characteristics [36]. Intratumoral
injection of CXCL10 leads to reduced growth and impaired
angiogenesis and metastasis in murine adenocarcinoma and
studies have shown a synergistic effect against tumours
through its immunomodulatory properties in murine models
of glioma and melanoma [37–39]. Both CXCL10 and its
receptor CXCR3 are on the other hand over-expressed in
many tumours and have been connected to poor prognosis
and metastasis in a number of cancers, including colon cancer,
multiple myeloma, breast cancer and basal cell carcinoma
[40–44]. Simultaneous expressions of CXCL10 and CXCR3
in breast cancer cell lines additionally lead to CXCL10-
dependent proliferation of CXCR3-positive cells and treat-
ments using CXCR3 antagonists, and ligand-neutralizing an-
tibodies inhibit metastasis in melanoma and breast cancer in
mice [45–47]. Explanations to the dual role of CXCL10 as
both a tumour inhibitor and a tumour promoter can be many;
the receptor CXCR3, for example, exists in three isoforms
(CXCR3-A CXCR3-B and CXCR3-alt) with different out-
comes upon activation, and the balance between the three
could be of importance; structural properties of CXCL10 are
thought to be significant for in vivo activity, and the effect of
CXCL10 signalling is suggested to vary depending on wheth-
er the microenvironment or the tumour cells express the
receptor [36, 48, 49]. Treatments targeting CXCL10 therefore
have to be used with care today, and it is important to fully
understand the role of CXCL10 in individual tumour types
and subgroups of tumours.
CXCR1 is the only chemokine in our study showing sig-
nificant down-regulation. CXCR1 together with CXCR2 rep-
resent the two angiogenic receptors even though CXCR2 is
considered the major angiogenic receptor in humans [50]. The
two ligands for CXCR1, CXCL6 and CXCL8, which also
activate CXCR2, are both up-regulated, indicating that a shift
towards activation of CXCR2 could be of importance for
tongue carcinoma. Antibody-based inhibition of CXCR2 in
pancreatic cancer models has previously been shown to block
angiogenesis with an accompanying reduction in tumour
growth, and a recent study of CXCR2 and oral cancer showed
antagonist inhibition of CXCR2 to decrease tumour cell
viability [51–53].
The main limitation of this study is the restricted number of
available samples. We included all tongue tumour patients
treated at Norrlands University Hospital between 1998 and
2010 that had gone through preoperative radiotherapy and
surgery and for which there were an available tumour sample
from diagnosis. Still, only 12 patients with a non-cPR were
available and confirmation of our result in an independent
dataset will be important. The arrays from which we retrieve
the expression data contains probes for 20 818 genes. If we
were to test them all, the very stringent and commonly used
Bonferroni correction would be applied, and the significance
level would be set to p<2.4E-6. This would result in only
CXCL1 and CXCL10 being considered significantly up-
regulated (Fig. 2). The Bonferroni correction ensures that the
majority of the identified genes in large-scale experiments are
true positives but simultaneously reduces the sensitivity of the
analysis. The present study was, even though utilizing micro-
array data, based on a prior hypothesis and investigating a
limited number of genes, and we therefore did not take mul-
tiple testing into consideration.
In conclusion, we have comprehensively characterized the
expression of the CXC-chemokine ligands and their receptors
in tongue tumours. We have correlated their expression to
pathological response to radiotherapy and found that especial-
ly a group of patients with highly increased expression of
CXCL10 is associated with non-complete response, indicat-
ing a role for this gene in resistance to radiotherapy. Addition-
ally, we have confirmed the importance of cPR for overall
survival of tongue carcinoma patients. Taken together, our
data identify high-level CXCL10 expression as a predictive
biomarker for poor response to radiotherapy in tongue can-
cers. These patients may therefore benefit from alternative
treatments, possibly involving specific targeting of CXCL10.
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